NCT01391299View on ClinicalTrials.gov

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines

NACompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

June 1, 2011

Primary Completion Date

October 18, 2011

Study Completion Date

February 28, 2012

Conditions
Facial RhytidesGlabellar Frown Lines
Interventions
BIOLOGICAL

botulinum toxin Type A

Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.

DRUG

Normal Saline

Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.

Trial Locations (1)

Unknown

Toronto

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY